In CKD without diabetes, finerenone vs. placebo slowed kidney function decline over 32 mo

Authors

Institutions

Publication Details

Journal
Annals of Internal Medicine
Published
2026-10-05
DOI
https://doi.org/10.7326/annals-26-03577-jc
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In CKD without diabetes, finerenone vs. placebo slowed kidney function decline over 32 mo

Shubha Ananthakrishnan
Annals of Internal Medicine
Chronic Kidney Disease and Diabetes
article

In CKD without diabetes, finerenone vs. placebo slowed kidney function decline over 32 mo

Shubha Ananthakrishnan
article en

Abstract

No abstract available for this paper.
Annals of Internal Medicine
University of California, Davis (US)
Good health and well-being
Openalex Percentile: Top 12%
Chronic Kidney Disease and Diabetes
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In CKD without diabetes, finerenone vs. placebo slowed kidney function decline over 32 mo — Shubha Ananthakrishnan · Annals of Internal Medicine (2026) | TGRS Research Map | TGRS